ClinicalTrials.gg
RecruitingNCT05765981Updated Mar 13, 2023

An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

An Early Phase 1 interventional study of VGN-R09b in Aromatic L-amino Acid Decarboxylase (AADC) Deficiency, sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 24 Months to 7 Years. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
24 Months to 7 Years
Sex
All
01

Study summary

This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.

Read the detailed description

Aromatic L-amino acid decarboxylase (AADC) is an enzyme responsible for the final step in the synthesis of neurotransmitters dopamine and serotonin. AADC deficiency is a rare genetic disorder. VGN-R09b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human AADC (hAADC) being injected directly into striatum.

This is a single-center, open, dose-climbing investigator-sponsored early-stage clinical study that included a dose-climbing phase and a dose-expanding phase.

This study is to give preliminary evidence for the safety and efficacy of VGN-R09b treatment for patients with Aromatic L-amino acid decarboxylase (AADC) deficiency.

02

Conditions studied

  • Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Keywords

  • AADC, AAV9, CNS gene therapy
03

In context

Lead sponsor

Shanghai Jiao Tong University School of Medicine is the lead sponsor of 374 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Months to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The child patient has to be ≥2 years old and \< 8 years old, or a head circumference big enough for surgery.
  2. Historical diagnosis of AADC deficiency with clinical symptoms consistency, AND confirmed by one of the lab tests: (1) CSF neurotransmitter profile demonstrating reduced HVA and 5-HIAA, and elevated L-Dopa concentrations; (2) Plasma AADC activity less than or equal to 5 pmol/min/mL, AND with Molecular genetic confirmation of homozygous or compound heterozygous mutation of IVS6+4A>T in DDC.
  3. Motor development at baseline ≤3 months, and Failed to benefit from standard medical therapy (dopamine agonists, monoamine oxidase inhibitor or related form of Vitamin B6) at discretion of investigators.
  4. Stable medication regimen for treatment of AADC deficiency: (i.e. no new medications introduced for at least 6 months, and no existing medication dose changes for at least 3 months prior to Baseline).
  5. Parent(s)/legal guardian(s) with custody of subject must give their consent for subject to enroll in the study
  6. Parent(s)/legal guardian(s) of the subject must agree to comply with the requirements of the study, including providing disease information and support disease assessment of symptoms.

Exclusion criteria

Exclusion Criteria:

  1. Intracranial neoplasm or any structural brain abnormality or lesion (e.g., severe brain atrophy, white matter degenerative changes), which, in the opinion of the study investigators, would confer excessive risk and/or inadequate potential for benefit.
  2. Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk (including congenital heart disease, respiratory disease with home oxygen requirement, history of serious anesthesia complications during previous elective procedures, history of cardiorespiratory arrest), liver or renal failure, , or positive.
  3. Severe coagulopathy, or need for ongoing anticoagulant therapy.
  4. clinically active infection or with severe infection within 12 weeks before screening (e.g. adenovirus or herpes virus, pneumonia, sepsis, central nervous system infection).
  5. Previous stereotactic neurosurgery, or any gene/cell therapy.
  6. Received within 4 weeks.
  7. Patients with anti-AAV9 neutralizing antibody titer over 1,200 folds.
  8. to sedation during surgery or imaging studies (PET or MRI).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Aromatic L-amino acid decarboxylase (AADC) deficiency

    This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.

    Drug: VGN-R09b

Interventions

  • DrugVGN-R09b

    VGN-R09b will be injected into bilateral putamen by stereotactic surgery.(Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center)

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs)

    Number of Adverse Events (AEs), Serious Adverse Events (SAEs)

    Time frame: Week 52

  2. Achievement Ratio of the four motor development milestones (Head control, Sit independently, Stand/stepping with support and Walk with minimal assistant)

    Achievement Ratio of the four motor development milestones (Head control, Sit independently, Stand/stepping with support and Walk with minimal assistant) according to PDMS-II score.

    Time frame: Week 52

07

Study locations

1 of 1 sites recruiting
  • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, No. 1678, Dongfang Road, Pudong New Area, Shanghai 200127, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Feb 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2023
First posted
Mar 13, 2023
StartActual
Jan 30, 2023
Primary completionEst.
Feb 20, 2025
CompletionEst.
Feb 20, 2029
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05765981
Collaborators
Shanghai Vitalgen BioPharma Co., Ltd.
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Jan 30, 2023
Primary completion
Feb 20, 2025 (estimated)
Completion
Feb 20, 2029 (estimated)
Last update
Mar 13, 2023

Study contacts

Jiwen Wang, Doctor
Contact
wangjiwen@scmc.com.cn
18916613192
Jiwen Wang, Doctor
study chair · Shanghai Children's Medical Center, affiliated to Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion